The Exploratory Study to Investigate the Effect of Ramelteon for Insomnia Patients With Major Depressive Disorder by Using Actigraphy

NCT ID: NCT02669082

Last Updated: 2019-07-22

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE4
• Total Enrollment: 26 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2017-05-09
• Study Completion Date: 2018-01-31

Brief Summary

The purpose of this study is to investigate exploratorily the effect of ramelteon 8 mg once daily for 8 weeks in the treatment of insomnia patients with depression by using actigraphy.

Detailed Description

The drug being tested in this study is called ramelteon. Ramelteon is being tested to treat people who have insomnia with depression. This study will look at sleep activity of participants who take ramelteon.

The study will enroll approximately 30 patients. Participants will be administered:

• Ramelteon 8 mg

Participants will be asked to take 1 tablet orally at bedtime. This multi-center study will be conducted in Japan. The overall period to participate in this study is 9 weeks (Run-in period for 1 week and treatment period for 8 weeks). Participants will make multiple visits to clinic including the final visit 8 weeks after the start of treatment.

Conditions

Insomnia; Major Depressive Disorder

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Ramelteon 8 mg

Ramelteon 8 mg, tablet, orally, once daily at bedtime for 8 weeks.

Group Type: EXPERIMENTAL

Ramelteon

Intervention Type: DRUG

Ramelteon tablets

Interventions

Ramelteon

Ramelteon tablets

Intervention Type: DRUG

Other Intervention Names

Rozerem; TAK-375

Eligibility Criteria

Inclusion Criteria

1. Has difficulty in initiating sleep at least 3 days per week for at least 4 weeks at the time of informed consent.

2. Has Diagnostic and Statistical Manual of Mental Disorders Fifth Edition (DSM-5)-defined depression.

3. Man or woman between 20 and 64 years of age, inclusive, at the time of informed consent.

4. Outpatient.

5. Meets either of the following criteria based on the 17-item Hamilton Rating Scale for Depression (HAM-D17) both at the start of the run-in period and the start of the study treatment period: has a score of 2 for "6: Insomnia Early", or has a score of 1 for "6: Insomnia Early" AND a score of at least 3 in total for "7: Insomnia Middle" and "8: Insomnia Late".

6. Has a total HAM-D17 score of 16 or under both at the start of the run-in period and the start of the study treatment period.

7. Under treatment of the same antidepressant agents on a stable dose for at least 4 weeks before the start of the run-in period.

8. Goes to bed routinely in a daily life (time for bed between 21.00 p.m. and 1.00 a.m. at least 4 days per week).

9. Actigraphy shows at least 3 days with sleep latency 30 minutes or longer AND total nocturnal sleep time 6.5 hours or shorter on the same day during the run-in period.

10. In the opinion of the principal investigator or investigator, is capable of understanding the contents of the study and complying with study requirements.

11. Is capable of signing and dating the informed consent form in person before any study procedures.

Exclusion Criteria

1. Has a history of hypersensitivity to ramelteon and melatonin.

2. Has severe liver disorder.

3. Took ramelteon within 4 weeks before the informed consent.

4. Using any insomnia medications (including investigational drugs and unapproved drugs) for 2 weeks before the treatment period.

5. Shift worker or night worker.

6. Has complications of psychiatric or neurological diseases that affect sleep state other than depression.

7. Has a HAM-D17 score of at least 1 for"11: Suicide" at the start of the run-in period or the start of the study treatment period, or any suicide attempts within 24 weeks before or during the run-in period.

8. Pregnant woman, nursing mother, or woman who plans to become pregnant or donate eggs before the informed consent, during the study period or within 4 weeks after the end of the study.

9. Is participating in any other investigational or post-marketing clinical trial/study.

10. For other reason, judged not appropriate for participation in this study by the principal investigator or investigator.

• Minimum Eligible Age: 20 Years
• Maximum Eligible Age: 64 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Takeda

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Study Director

Role: STUDY_DIRECTOR

Takeda

Locations

You Ariyoshi Sleep Clinic

Kitakyushu, Fukuoka, Japan

Ishikawa Mental Clinic

Sapporo, Hokkaido, Japan

Minami 1jo Mental Clinic

Sapporo, Hokkaido, Japan

Senzoku Psychosomatic Clinic

Meguro City, Tokyo, Japan

Sangenjaya Neurology and Psychosomatic Clinic

Setagaya City, Tokyo, Japan

Himorogi Kokorono Clinic

Shinjuku, Tokyo, Japan

Seiwa Hospital

Shinjuku, Tokyo, Japan

Countries

Japan

Provided Documents

Document Type: Statistical Analysis Plan

View Document

Document Type: Study Protocol

View Document

Other Identifiers

JapicCTI-163143

Identifier Type: REGISTRY

Identifier Source: secondary_id

U1111-1177-4116

Identifier Type: OTHER

Identifier Source: secondary_id

Ramelteon-4002

Identifier Type: -

Identifier Source: org_study_id